The GPATCH4 Knockout HeLa Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population in which the target gene GPATCH4 has been disrupted to generate a loss-of-function model in the HeLa cell background. This mixed population offers a versatile tool for studying gene function without the selective pressures of clonal isolation, enabling robust analysis in a genetically heterogeneous context that more closely reflects natural cell populations.
HeLa cells are an epithelial cell line derived from cervical adenocarcinoma, characterized by the presence of HPV18 sequences that inactivate the p53 and retinoblastoma (Rb) tumor suppressors. This genetic background drives unchecked proliferation and genomic instability, establishing HeLa as a widely employed model in cancer biology and gene expression research. The cell line??s proficient spliceosome machinery supports detailed investigation of pre-mRNA processing pathways, making it an ideal host for studying splicing-related gene perturbations.
GPATCH4 encodes a protein containing a G-patch domain, a motif associated with RNA binding and activation of RNA helicases. Functionally, GPATCH4 serves as a cofactor for spliceosomal RNA helicases, facilitating critical steps in pre-mRNA splicing. It interacts with core components of the spliceosome, including the scaffold protein PRP8 and U5 snRNP, and is connected to the SF3B complex within the U2 snRNP, placing it at a central node of spliceosome assembly and catalytic activation. Upstream, its expression and activity are influenced by transcription factors that govern splicing machinery components and by cell cycle signals that coordinate splicing with cellular proliferation. Disruption of GPATCH4 leads to altered splicing of downstream target genes, producing aberrant isoforms and disrupting normal RNA processing intermediate pools.
In the HeLa adenocarcinoma context, where HPV-driven transformation and checkpoint inactivation create a permissive environment for aberrant splicing, GPATCH4 knockout reveals how loss of a helicase cofactor impacts cancer cell phenotypes. This model is particularly relevant for investigating the role of splicing dysregulation in tumor progression and for exploring splicing-related disorders. By removing a key regulatory component, researchers can probe the dependency of malignant cells on specific splicing events and identify vulnerabilities tied to spliceosome function in a high-proliferative, HPV-positive background.
Researchers can deploy this polyclonal knockout population across diverse experimental workflows. Representative assays include RT-PCR to resolve alternative splicing isoform patterns, RNA immunoprecipitation to study protein?CRNA interactions, western blotting to assess spliceosomal protein levels, immunofluorescence to visualize subnuclear localization to speckles, and RNA sequencing to globally map splicing alterations. Applications span the investigation of alternative splicing regulation, cancer cell biology, RNA processing mechanisms, and validation of drug targets aimed at splicing modulators. For additional details or custom inquiry, please contact Ascent Research.
